# GAIN-BCG (NCT07000084)

> Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy

No report yet. It can be ordered.

- Indication: recurrent BCG-exposed high-grade non-muscle-invasive bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07000084
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Recurrent Non-Muscle Invasive Bladder Carcinoma; Stage 0a Bladder Cancer AJCC v8; Stage I Bladder Cancer AJCC v8
- Interventions: BCG Solution; Biopsy of Bladder; Cystoscopy; Computed Tomography; Magnetic Resonance Imaging; Biospecimen Collection; Transurethral Resection of Bladder Tumor; Gemcitabine
- Enrollment: 330
- Primary outcome: High Grade Recurrence-free survival (HG-RFS)

## Indexed commentary on GAIN-BCG so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=gain-bcg-nct07000084